Drugs.com New Drug ApplicationsOriginal article
Outlook Therapeutics Announces FDA Acceptance of Resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) as a Treatment for Wet AMD
BLA FilingONS-5010/LytenavaPositive
AI Analysis
Summary
Outlook Therapeutics announced FDA acceptance of a resubmitted Biologics License Application for ONS-5010/Lytenava (bevacizumab-vikg) for the treatment of wet age-related macular degeneration, advancing the candidate toward potential approval.
Outcome Details
FDA acceptance of resubmitted Biologics License Application
Importance:7/10
Sentiment:
0.70
BLA acceptancebevacizumabwet AMDophthalmologyresubmissionregulatory approval pathway
Related Companies
Read the original article
Published by Drugs.com New Drug Applications on June 16, 2026 9:06 PM